Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir + Peg-IFN + RBV in Treatment-Naive Genotype 1 HCV
NCT00895882Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Nov 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vaniprevir in hepatitis C (HCV) (6 arms), sponsored by Merck & Co. Primary endpoints: Proportion of patients achieving Sustained Virologic Response 24 weeks after end of study therapy and Safety and tolerability of MK7009 treatment regimens at 72 Weeks. Planned start Nov 2010; status: withdrawn.
02
Drugs
vaniprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00895882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895882.